Sfoglia per Autore
Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.
1999-01-01 Berruti, Alfredo; Dogliotti, L; Fasolis, G; Mosca, A; Tarabuzzi, R; Torta, M; Mari, M; Fontana, D; Angeli, A.
Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.
1999-01-01 Berruti, Alfredo; L., Dogliotti; Gorzegno, G.; Torta, M.; Tampellini, M.; Tucci, M.; Cerutti, S.; Frezet, M. M.; Stivanello, M.; Sacchetto, G.; Angeli, A.
Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience.
1999-01-01 Berruti, Alfredo; Borasio, P.; Gerbino, A.; Gorzegno, G.; Moschini, T.; Tampellini, M.; Ardissone, F.; Brizzi, M. P.; Dolcetti, A.; Dogliotti, L.
Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells.
1999-01-01 Villa, R; Orlandi, L; Berruti, Alfredo; Dogliotti, L; Zaffaroni, N.
Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases
1999-01-01 Berruti, A.; Dogliotti, L.; Gorzegno, G.; Torta, M.; Tampellini, M.; Tucci, M.; Cerutti, S.; Frezet, M. M.; Stivanello, M.; Sacchetto, G.; Angeli, A.
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
2000-01-01 Bottini, A; Berruti, Alfredo; Bersiga, A; Brizzi, Mp; Brunelli, A; Gorzegno, G; Dimarco, B; Aguggini, S; Bolsi, G; Cirillo, F; Filippini, L; Betri, E; Bertoli, G; Alquati, P; Dogliotti, L.
Circulating neuroendocrine markers in patients with prostate carcinoma.
2000-01-01 Berruti, Alfredo; Dogliotti, L; Mosca, A; Bellina, M; Mari, M; Torta, M; Tarabuzzi, R; Bollito, E; D., Fontana; Angeli, A.
Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.
2000-01-01 Terzolo, M; Pia, A; Berruti, Alfredo; Osella, G; Ali, A; Carbone, V; Testa, E; Dogliotti, L; Angeli, A.
Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines
2000-01-01 Berruti, Alfredo; Sperone, P; Bottini, A; Gorzegno, G; Lorusso, V; Brunelli, A; Botta, M; Tampellini, M; Donadio, M; Mancarella, S; DE LENA, M; Alquati, P; Dogliotti, L.
Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.
2000-01-01 Berruti, Alfredo; Dogliotti, L; Bitossi, R; Fasolis, G; Gorzegno, G; Bellina, M; Torta, M; Porpiglia, F; Fontana, D; Angeli, A.
Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment.
2000-01-01 Berruti, Alfredo; Dogliotti, L; Osella, G; Cerutti, S; Reimondo, G; Martino, A; Gorzegno, G; Catolla, R; Angeli, A.
Low dose carboplatin (AUC 4.5) combined with vinorelbine in the treatment of advanced non-small cell lung cancer: a single institution phase II study.
2001-01-01 Bretti, S; Manzin, E; Celano, A; Ritorto, G; Loddo, C; Berruti, Alfredo
Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse.
2001-01-01 Tampellini, M; Berruti, Alfredo; Gorzegno, G; Bitossi, R; Bottini, A; Durando, A; DE MATTEIS, A; Farris, A; Donadio, M; DE FABIANI, E; Manzin, E; Arese, P; Sarobba, Mg; Castiglione, F; Moro, G; Bonazzi, G; Nuzzo, F; Massobrio, M; Dogliotti, L.
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease
2001-01-01 Fiorentino, C.; Berruti, A.; Bottini, A.; Bodini, M.; Brizzi, M. P.; Brunelli, A.; Marini, U.; Allevi, G.; Aguggini, S.; Tira, A.; Alquati, P.; Olivetti, L.; Dogliotti, L.
Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.
2001-01-01 Bollito, E; Berruti, Alfredo; Bellina, M; Mosca, A; Leonardo, E; Tarabuzzi, R; Cappia, S; Ari, Mm; Tampellini, M; Fontana, D; Gubetta, L; Angeli, A; Dogliotti, L.
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial
2001-01-01 Donadio, M.; Manzin, E.; Berruti, A.; Bottini, A.; Gorzegno, G.; Danese, S.; Defabiani, E.; Sarobba, M. G.; Lorusso, V.; Castiglione, F.; Moro, G.; Bertetto, O.; Bumma, C.; Dogliotti, L.
Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience.
2001-01-01 Stivanello, M; Berruti, Alfredo; Torta, M; Termine, A; Tampellini, M; Gorzegno, G; Angeli, A; Dogliotti, L.
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease.
2001-01-01 Fiorentino, C; Berruti, Alfredo; Bottini, A; Bodini, M; Brizzi, Mp; Brunelli, A; Marini, U; Allevi, G; Aguggini, S; Tira, A; Alquati, P; Olivetti, L; Dogliotti, L.
Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.
2001-01-01 Berruti, Alfredo; Dogliotti, L; Mosca, A; Gorzegno, G; Bollito, E; Mari, M; Tarabuzzi, R; Poggio, M; Torta, M; Fontana, D; Angeli, A.
Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.
2001-01-01 Berruti, Alfredo; Dogliotti, L; Tucci, M; Tarabuzzi, R; D., Fontana; Angeli, A.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer. | 1-gen-1999 | Berruti, Alfredo; Dogliotti, L; Fasolis, G; Mosca, A; Tarabuzzi, R; Torta, M; Mari, M; Fontana, D; Angeli, A. | |
| Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. | 1-gen-1999 | Berruti, Alfredo; L., Dogliotti; Gorzegno, G.; Torta, M.; Tampellini, M.; Tucci, M.; Cerutti, S.; Frezet, M. M.; Stivanello, M.; Sacchetto, G.; Angeli, A. | |
| Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. | 1-gen-1999 | Berruti, Alfredo; Borasio, P.; Gerbino, A.; Gorzegno, G.; Moschini, T.; Tampellini, M.; Ardissone, F.; Brizzi, M. P.; Dolcetti, A.; Dogliotti, L. | |
| Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. | 1-gen-1999 | Villa, R; Orlandi, L; Berruti, Alfredo; Dogliotti, L; Zaffaroni, N. | |
| Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases | 1-gen-1999 | Berruti, A.; Dogliotti, L.; Gorzegno, G.; Torta, M.; Tampellini, M.; Tucci, M.; Cerutti, S.; Frezet, M. M.; Stivanello, M.; Sacchetto, G.; Angeli, A. | |
| p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. | 1-gen-2000 | Bottini, A; Berruti, Alfredo; Bersiga, A; Brizzi, Mp; Brunelli, A; Gorzegno, G; Dimarco, B; Aguggini, S; Bolsi, G; Cirillo, F; Filippini, L; Betri, E; Bertoli, G; Alquati, P; Dogliotti, L. | |
| Circulating neuroendocrine markers in patients with prostate carcinoma. | 1-gen-2000 | Berruti, Alfredo; Dogliotti, L; Mosca, A; Bellina, M; Mari, M; Torta, M; Tarabuzzi, R; Bollito, E; D., Fontana; Angeli, A. | |
| Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. | 1-gen-2000 | Terzolo, M; Pia, A; Berruti, Alfredo; Osella, G; Ali, A; Carbone, V; Testa, E; Dogliotti, L; Angeli, A. | |
| Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines | 1-gen-2000 | Berruti, Alfredo; Sperone, P; Bottini, A; Gorzegno, G; Lorusso, V; Brunelli, A; Botta, M; Tampellini, M; Donadio, M; Mancarella, S; DE LENA, M; Alquati, P; Dogliotti, L. | |
| Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. | 1-gen-2000 | Berruti, Alfredo; Dogliotti, L; Bitossi, R; Fasolis, G; Gorzegno, G; Bellina, M; Torta, M; Porpiglia, F; Fontana, D; Angeli, A. | |
| Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. | 1-gen-2000 | Berruti, Alfredo; Dogliotti, L; Osella, G; Cerutti, S; Reimondo, G; Martino, A; Gorzegno, G; Catolla, R; Angeli, A. | |
| Low dose carboplatin (AUC 4.5) combined with vinorelbine in the treatment of advanced non-small cell lung cancer: a single institution phase II study. | 1-gen-2001 | Bretti, S; Manzin, E; Celano, A; Ritorto, G; Loddo, C; Berruti, Alfredo | |
| Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. | 1-gen-2001 | Tampellini, M; Berruti, Alfredo; Gorzegno, G; Bitossi, R; Bottini, A; Durando, A; DE MATTEIS, A; Farris, A; Donadio, M; DE FABIANI, E; Manzin, E; Arese, P; Sarobba, Mg; Castiglione, F; Moro, G; Bonazzi, G; Nuzzo, F; Massobrio, M; Dogliotti, L. | |
| Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease | 1-gen-2001 | Fiorentino, C.; Berruti, A.; Bottini, A.; Bodini, M.; Brizzi, M. P.; Brunelli, A.; Marini, U.; Allevi, G.; Aguggini, S.; Tira, A.; Alquati, P.; Olivetti, L.; Dogliotti, L. | |
| Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. | 1-gen-2001 | Bollito, E; Berruti, Alfredo; Bellina, M; Mosca, A; Leonardo, E; Tarabuzzi, R; Cappia, S; Ari, Mm; Tampellini, M; Fontana, D; Gubetta, L; Angeli, A; Dogliotti, L. | |
| Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial | 1-gen-2001 | Donadio, M.; Manzin, E.; Berruti, A.; Bottini, A.; Gorzegno, G.; Danese, S.; Defabiani, E.; Sarobba, M. G.; Lorusso, V.; Castiglione, F.; Moro, G.; Bertetto, O.; Bumma, C.; Dogliotti, L. | |
| Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. | 1-gen-2001 | Stivanello, M; Berruti, Alfredo; Torta, M; Termine, A; Tampellini, M; Gorzegno, G; Angeli, A; Dogliotti, L. | |
| Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. | 1-gen-2001 | Fiorentino, C; Berruti, Alfredo; Bottini, A; Bodini, M; Brizzi, Mp; Brunelli, A; Marini, U; Allevi, G; Aguggini, S; Tira, A; Alquati, P; Olivetti, L; Dogliotti, L. | |
| Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. | 1-gen-2001 | Berruti, Alfredo; Dogliotti, L; Mosca, A; Gorzegno, G; Bollito, E; Mari, M; Tarabuzzi, R; Poggio, M; Torta, M; Fontana, D; Angeli, A. | |
| Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. | 1-gen-2001 | Berruti, Alfredo; Dogliotti, L; Tucci, M; Tarabuzzi, R; D., Fontana; Angeli, A. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile